How fast do people lose weight on Wegovy?

What does the trial data actually show about the pace of weight loss?

The clearest picture comes from the STEP 1 trial, published in the New England Journal of Medicine. Over 68 weeks, adults taking semaglutide 2.4mg alongside a reduced-calorie diet and increased activity lost an average of around 15% of their starting body weight, compared with around 2.4% in the placebo group. That is an average, some participants lost considerably more, others less.

The loss was not steady throughout. Most people saw a noticeable drop in the first month, partly because appetite falls fairly quickly once semaglutide begins working on GLP-1 receptors in the brain. The sharpest phase of loss then tends to come between roughly months two and six, as the dose steps up every four weeks from the 0.25mg starting point toward the 2.4mg maintenance level. After that, the curve flattens. Slower loss in later months is normal, the body is reaching a new equilibrium, not stalling.

It is also worth knowing that the newer 7.2mg dose, approved by the MHRA in January 2026 and given as a dedicated single-dose pen from April 2026, produced around 20.7% average weight loss over 72 weeks in trials. That narrows the gap with tirzepatide considerably, though access to this dose depends on clinical suitability confirmed at assessment.

If you are curious about how the typical timeline maps to months rather than weeks, our page on how long Wegovy takes to work breaks it down dose-step by dose-step.

Why do some people lose weight faster than others on Wegovy?

Several factors shape individual pace. Starting body weight matters: someone with a higher BMI often sees larger absolute losses early on, even if the percentage is similar. Metabolic rate, activity levels, dietary changes, sleep quality, and whether other conditions such as type 2 diabetes or hypothyroidism are present all play a role.

Dose progression is also a significant variable. Wegovy's schedule starts at 0.25mg specifically to let the body adjust, nausea and other gastrointestinal effects are more manageable that way. Rushing the titration is not an option; each step needs around four weeks, and some people stay on an intermediate dose longer if side effects are troublesome. That means faster dose escalation does not equal faster weight loss: the body sets the pace.

Adherence to lifestyle changes is probably the largest modifiable factor. The trial results were achieved alongside diet and activity support. Treatment is most effective as one part of a broader change rather than something that works in isolation.

One thing our prescribers hear often: people worry that a slow first few weeks means the medicine is not working. That early phase is adjustment, not failure. Give it time before drawing conclusions, and speak to your clinical team if you are unsure what to expect at your current dose.

How does the oral Wegovy tablet compare on speed of results?

Since the MHRA approved Wegovy tablets on 11 June 2026, making the UK the first country in Europe to licence an oral GLP-1 medicine for weight management, this is one of the questions our prescribers are fielding most often.

The OASIS 4 trial (307 adults, 64 weeks, oral semaglutide at its 25mg maintenance dose versus placebo) reported an average weight loss of around 13.6% regardless of adherence, rising to roughly 17% among participants who stayed fully consistent with treatment throughout. That is a meaningful result for a tablet, though it sits slightly below the 2.4mg injection's 15% average and well below the 7.2mg injection data.

The pace is broadly comparable in pattern to the injection, gradual early, faster through the middle dose steps, then a plateau. The tablet's titration runs from 1.5mg through 4mg and 9mg to 25mg, with at least a month at each level. The practical upside is the absence of injections and no refrigeration needed, which some people find makes consistency easier over the long term. Worth considering if the visual results data matters to your decision.

For a fuller look at how treatment duration affects outcomes (including what happens if you stop) see our guide on how long people typically take Wegovy.

Is Wegovy fast enough, and how do you know when it is working?

The honest answer is that Wegovy is not a rapid-weight-loss tool. It is a licensed medicine that produces clinically significant, sustained weight reduction over months, not days. NICE guidance, reflected in the TA875 recommendation for semaglutide, suggests reassessing whether to continue if less than 5% weight loss has occurred after six months on the maintenance dose. That is the formal benchmark, not a target to hit in week one.

In practice, the signs that treatment is working often come before the scales shift noticeably. Appetite reducing at meals, feeling satisfied sooner, thinking about food less between meals, these tend to appear in the first two to four weeks. Weight follows. If you are wondering how your experience compares to what people describe at different points in their treatment, our page on the typical Wegovy weight-loss timeline covers this in more detail.

One practical note on timing: orders placed before 12pm on a working day, once clinically approved, are dispatched the same day for free next-working-day delivery with DPD. If you are thinking about starting before a holiday or around a payday, it is worth factoring that lead time in rather than leaving it to the last minute. For anything specific to your situation, speak to our prescribers, they review consultations the same day, not via an automated queue.

Questions about the cost of Wegovy in the UK, or about typical treatment duration, are also worth exploring before starting.